Feb 22, 2018 - The following slide deck was published by Blueprint Medicines in conjunction with their 2017 Q4 earnings call.
Feb 21, 2018 - Blueprint Medicines. (NASDAQ:BPMC) Q4 2017 Results Earnings Conference Call February 21, 2018, 08:30 AM ET Executives Kristin Hodous - Investor Relations Jeff Albers - Chief Executive Officer Andy Bor
Feb 21, 2018 - Blueprint Medicines (BPMC) Q4 results: Revenues: $1.6M (-79.2%); Net Loss: ($49M); Loss Per Share: ($1.23) (-64.0%); Quick Assets: $673.4M.Financial Guidance: Blueprint Medicines expects that its exis
Jan 26, 2018 - Biotech sector starts off the year strong with multiple acquisitions and partnerships, beginning to usher in the long-awaited M&A boom.Furthermore, unlike last October, earnings season this time has o
Jan 16, 2018 - Intuitive Surgical (ISRG) is expected to witness growth across da Vinci Surgical and Service segments. Instruments and accessories revenues are also expected to increase year over year.
Dec 19, 2017 - Biotechnology delivered a solid year in 2017, overcoming the poor performance in 2016.Multiple reasons for Biotechs to continue performing strongly in 2018.On a relative basis, Biotechs represent a go
Dec 15, 2017 - Shares have risen well over 200% since my initial write-up on this nascent leader in targeted oncology.Results in GIST and SM have been quite impressive.After the recent secondary, the company has sig
Dec 14, 2017 - Regeneron is significantly undervalued at current levels. Eli Lilly has provided guidance for 2018. Bluebird has announced a public offering.
Dec 12, 2017 - The following slide deck was published by Blueprint Medicines in conjunction with this event.
Dec 12, 2017 - Blueprint Medicines (BPMC) announced Sunday that its Phase 1 trial of avapritinib showed strong clinical activity.